LYELL IMMUNOPHARMA IN

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

07 Nov 2022 08:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Credit Suisse Healthcare Conference

02 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of its IND for LYL845, a TIL Product Candidate Enhanced with its Novel Epigenetic Reprogramming Technology for Solid Tumors

06 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces the Appointment of Rahsaan Thompson as Chief Legal Officer

28 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Presents First in Human Trial Design of LYL797 at ESMO 2022

12 Sep 2022 03:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Morgan Stanley Global Healthcare Conference

30 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights

04 Aug 2022 16:05:03 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in Goldman Sachs Global Healthcare Conference

07 Jun 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights

10 May 2022 16:05:02 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in BofA Securities Healthcare Conference

04 May 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

29 Mar 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces Upcoming Presentation on LYL797 at the American Association for Cancer Research (AACR) 2022 Annual Meeting

08 Mar 2022 16:45:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer

31 Jan 2022 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of IND for LYL132, a T-Cell Receptor Therapy for Solid Tumors Being Developed in Collaboration with GSK

24 Jan 2022 08:00:00 By Nasdaq GlobeNewswire

Lyell Immunopharma to Participate in 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 16:05:01 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces FDA Clearance of its IND for LYL797, a CAR T-Cell Therapy Incorporating Novel Reprogramming Technologies for Solid Tumors

16 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs

15 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Announces Return of Dr. Rick Klausner as Board Chair

02 Dec 2021 16:05:00 By Nasdaq GlobeNewswire

Lyell Immunopharma Reports Third Quarter 2021 Financial Results and Business Highlights

12 Nov 2021 08:00:02 By Nasdaq GlobeNewswire